As of April 30, 2025, 45% (18/40) of subjects experienced disease progression or death, with a median progression-free survival (mPFS) of 12.5 months (95% CI: 6.47-NA), and a median duration of ...

Sobi® (STO: SOBI) will have a strong scientific presence at this year's ERA congress in Vienna (4-7 June) with a total of eight presentations: six oral presentations and two posters. We are proud that ...

Investing.com -- Shares of Incyte (NASDAQ: INCY) climbed 7% today after the biopharmaceutical company announced that multiple ...

whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.

Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether ...

The oral presentation will feature detailed efficacy and safety results from the study of bexmarilimab in combination with standard-of-care (azacitidine) in frontline with HR-MDS and those with ...

Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals, said:"We are thrilled to see bexmarilimab's data receive acceptance for oral presentation at EHA, following similar recognition at MDS and ASCO.

have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congress taking place June 12-15, 2025, in Milan, Italy, and the International Conference on Malignant ...

The oral presentation will feature detailed efficacy and safety results from the study of bexmarilimab in combination with standard-of-care (azacitidine) in frontline with HR-MDS and those with ...

The data to be presented are summarized below: The oral presentation at EHA will feature new safety and longer follow-up data for GLPG5101 in 64 patients with R/R large B-cell lymphoma (DLBCL), mantle ...

The oral presentation at EHA will include updated safety, complete remission, minimal residual disease (MRD) clinical findings, and longer duration of follow-up. The tuspetinib-based TUS+VEN+AZA ...